Kodiak Sciences reported a net loss of $44.1 million for Q4 2024, an improvement from $59.5 million in Q4 2023. The company's cash and cash equivalents stood at $168.1 million, which is expected to support operations into 2026. Research and development expenses decreased significantly, driven by reduced manufacturing activities and equity award forfeitures.
Net loss for Q4 2024 was $44.1 million, an improvement from $59.5 million in Q4 2023.
Research and development expenses decreased to $31.8 million in Q4 2024 from $46.6 million in Q4 2023.
General and administrative expenses decreased to $14.4 million in Q4 2024 from $16.7 million in Q4 2023.
Cash and cash equivalents were $168.1 million at the end of Q4 2024, expected to fund operations into 2026.
Kodiak Sciences anticipates significant progress in its clinical trials for tarcocimab, KSI-501, and KSI-101, with key data readouts and regulatory milestones expected in 2026. The company also plans to advance its VETi program and pipeline of investigational therapies for retinal diseases.
Analyze how earnings announcements historically affect stock price performance